Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM in Patients With Septic Shock. A Randomised, Double-blind, Two-Stage, Placebo Controlled Study

NCT03158948 is registered in ClinicalTrials.gov with Inotrem as lead sponsor.

NCT NCT03158948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03158948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM in Patients With Septic Shock. A Randomised, Double-blind, Two-Stage, Placebo Controlled Study
Lead sponsor
Inotrem
Phase
Phase 2
Overall status
Completed
Start date
July 3, 2017
Completion date
June 13, 2018
Enrollment
50 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

shock, septic